News
Lilly focuses on tau with AC Immune Alzheimer's R&D tie-up
Eli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss biotech AC Immune, as focus shifts away from therapies targeting clumps
